Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Ventilator- associated pneumonia (VAP) is the most common hospital-acquired infections infection in the intensive care unit (ICU). Among the different bacteria causing severe infections in the ICU setting, P. aeruginosa is the most prevalent gram-negative bacterium for pneumonia. It is estimated that 20-25% of the hospital-acquired pneumonia infections are caused by P. aeruginosa. Every year roughly 450,500 patients in the USA, EU and Japan combined contract a hospital-acquired pneumonia caused by P. aeruginosa, representing approximately 21.5% of all HAP.

Multidrug resistant strains of P. aeruginosa are increasingly common in the hospital setting and this increasing prevalence threatens the effectiveness of potential treatment options. Thus, it is not surprising that the infection-related mortality of VAP caused by P. aeruginosa is high. In light of this increasing problem, there is clearly a high unmet medical need for new therapeutic options to fight P. aeruginosa infections.

To address this dangerous Gram negative bacteria, Aridis is developing separate immunotherapy options using the AR-101 mAb and Aerucin mAb, which could someday also be used in combination in a cocktail to further extend the efficacy potential. Current standard of care antibiotic treatments to manage P. aeruginosa pneumonia also require combination antibiotics.

P. aeruginosa and Pneumonia

P. Aeruginosa Virus


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home